On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Tridem Bioscience GmbH & Co KG's own share of each project, not the project's full budget.
- Horizon Europe€2.2M · 1 project
Projects
1 EU-funded project, newest first. Tridem Bioscience GmbH & Co KG led 1 of them as coordinator. Each links to the official record.
- NEXGEN-PDCoordinator
Next Generation Vaccine Platform Leveraging Skin Immunity to Provide Disease-Modifying Treatment of Parkinson’s Disease
Horizon Europe · 2023–2027 · Project on CORDIS ↗
€2.2Mtheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
- Philipps Universitaet MarburgGermany · 1 shared project
- Paracelsus Medizinische Privatuniversitat Salzburg - PrivatstiftungAustria · 1 shared project
- Modus Research and Innovation LimitedUnited Kingdom · 1 shared project
- Institute for Medical Technology Assessment BVNetherlands · 1 shared project
- Aurigon Labs Zartkoruen Mukodo ReszvenytarsasagHungary · 1 shared project
- Motac FranceFrance · 1 shared project
- Austrian Red Cross Research GmbHAustria · 1 shared project
- Gouya Insights GmbH & Co KGAustria · 1 shared project
- Prosenex Ambulatorium BetriebsgmbhAustria · 1 shared project
- Granzer Heinz UlrichGermany · 1 shared project
- Kineto Lab. Kutatas-Fejlesztesi Es Tanacsado KftHungary · 1 shared project
Fields it works in
Research fields recorded on its Horizon projects.
- pathology
- vaccines
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.